GMAB – Genmab A/S

Float Short %

1.81

Margin Of Safety %

Put/Call OI Ratio

0.88

EPS Next Q Diff

-0.5

EPS Last/This Y

0.21

EPS This/Next Y

-0.5

Price

33.88

Target Price

37.46

Analyst Recom

1.74

Performance Q

13.24

Relative Volume

1.01

Beta

0.9

Ticker: GMAB

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	GMAB	33.41	0.11	0.50	3701
2025-12-29	GMAB	32.51	0.11	1.00	3702
2025-12-30	GMAB	31.49	0.24	1.75	4831
2025-12-31	GMAB	30.79	0.25	0.12	4878
2026-01-02	GMAB	31.83	0.25	0.03	4874
2026-01-05	GMAB	31.78	0.25	2.11	4901
2026-01-06	GMAB	33.11	0.28	0.00	5073
2026-01-07	GMAB	33.92	0.25	0.08	5584
2026-01-08	GMAB	33.63	0.25	0.01	5666
2026-01-09	GMAB	34.24	0.24	0.17	5758
2026-01-12	GMAB	33.96	0.25	3.00	5757
2026-01-13	GMAB	33.88	0.27	12.47	5844
2026-01-14	GMAB	35.31	0.39	0.15	6379
2026-01-15	GMAB	33.88	0.40	4.31	6406
2026-01-16	GMAB	32.26	0.48	1.51	6795
2026-01-20	GMAB	31.32	0.61	4.39	5325
2026-01-21	GMAB	32.94	0.74	26.28	5731
2026-01-22	GMAB	33.11	0.88	0.81	6203
2026-01-23	GMAB	33.91	0.88	0.48	6265
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	GMAB	33.41	-49.5	161.5	1.92
2025-12-29	GMAB	32.52	-49.5	89.1	1.92
2025-12-30	GMAB	31.48	-49.5	79.7	1.92
2025-12-31	GMAB	30.79	-49.5	85.3	1.92
2026-01-02	GMAB	31.83	-49.5	156.0	1.92
2026-01-05	GMAB	31.79	-49.5	244.8	1.92
2026-01-06	GMAB	33.11	-49.5	334.1	1.92
2026-01-07	GMAB	33.90	-49.5	390.4	1.92
2026-01-08	GMAB	33.65	-49.5	132.6	1.92
2026-01-09	GMAB	34.24	-49.5	185.9	1.92
2026-01-12	GMAB	33.96	-49.5	136.9	1.92
2026-01-13	GMAB	33.87	-49.5	152.2	1.92
2026-01-14	GMAB	35.31	-49.5	258.7	1.92
2026-01-15	GMAB	33.87	-49.5	69.3	1.92
2026-01-16	GMAB	32.26	-49.5	50.2	1.92
2026-01-20	GMAB	31.33	-49.5	-24.5	1.92
2026-01-21	GMAB	32.95	-49.5	271.0	1.92
2026-01-22	GMAB	33.11	-48.2	160.5	1.92
2026-01-23	GMAB	33.88	-48.2	181.0	1.92
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	GMAB	0	0.51	1.87
2025-12-29	GMAB	0	0.51	1.87
2025-12-30	GMAB	0	0.51	1.87
2025-12-31	GMAB	0	0.51	1.87
2026-01-02	GMAB	0	0.51	1.87
2026-01-05	GMAB	0	0.53	1.87
2026-01-06	GMAB	0	0.53	1.87
2026-01-07	GMAB	0	0.53	1.87
2026-01-08	GMAB	0	0.53	1.87
2026-01-09	GMAB	0	0.53	1.87
2026-01-12	GMAB	0	0.53	1.87
2026-01-13	GMAB	0	0.53	1.81
2026-01-14	GMAB	0	0.53	1.81
2026-01-15	GMAB	0	0.53	1.81
2026-01-16	GMAB	0	0.53	1.81
2026-01-20	GMAB	0	0.45	1.81
2026-01-21	GMAB	0	0.45	1.81
2026-01-22	GMAB	0	0.45	1.81
2026-01-23	GMAB	0	0.45	1.81
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.65

Avg. EPS Est. Current Quarter

0.42

Avg. EPS Est. Next Quarter

0.15

Insider Transactions

Institutional Transactions

0.45

Beta

0.9

Average Sales Estimate Current Quarter

6550

Average Sales Estimate Next Quarter

6001

Fair Value

40.06

Quality Score

100

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-63.1

Target Price

37.46

P/E

14.39

Forward P/E

23.05

PEG

4.14

P/S

5.81

P/B

3.63

P/Free Cash Flow

16.71

EPS

2.35

Average EPS Est. Cur. Y

1.92

EPS Next Y. (Est.)

1.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

41.34

Relative Volume

1.01

Return on Equity vs Sector %

-2.1

Return on Equity vs Industry %

13.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

181

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 2681

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, Anthropic PBC, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

Float Short %

0.96

Margin Of Safety %

-15

Put/Call OI Ratio

0.87

EPS Next Q Diff

4.06

EPS Last/This Y

19.47

EPS This/Next Y

-0.37

Price

62.24

Target Price

61.57

Analyst Recom

2.27

Performance Q

16.64

Relative Volume

1.39

Beta

0.66

Ticker: NVO

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	NVO	52.39	0.72	0.29	1526521
2025-12-29	NVO	51.46	0.73	0.39	1454651
2025-12-30	NVO	51.24	0.73	0.42	1466616
2025-12-31	NVO	50.88	0.73	0.72	1476410
2026-01-02	NVO	52.4	0.74	0.39	1500952
2026-01-05	NVO	55.11	0.74	0.30	1457051
2026-01-06	NVO	56.19	0.74	0.39	1479901
2026-01-07	NVO	56.5	0.75	0.78	1507749
2026-01-08	NVO	57.36	0.77	1.22	1543044
2026-01-09	NVO	58.83	0.81	0.82	1593862
2026-01-12	NVO	59.85	0.81	0.75	1554726
2026-01-13	NVO	59.56	0.79	0.47	1560931
2026-01-14	NVO	58.9	0.79	0.43	1585092
2026-01-15	NVO	57.12	0.80	1.15	1606497
2026-01-16	NVO	62.32	0.84	0.42	1693378
2026-01-20	NVO	60.72	0.88	0.60	1328034
2026-01-21	NVO	59.32	0.84	0.64	1361008
2026-01-22	NVO	62.23	0.85	0.59	1422546
2026-01-23	NVO	62.27	0.87	0.35	1450815
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	NVO	52.41	-8.3	-1962.7	23.03
2025-12-29	NVO	51.45	-8.3	-2275.2	23.03
2025-12-30	NVO	51.20	-8.3	-1787.9	23.03
2025-12-31	NVO	50.88	-8.3	-1888.4	23.03
2026-01-02	NVO	52.40	-8.3	-1383.6	23.03
2026-01-05	NVO	55.13	-8.3	-676.6	23.03
2026-01-06	NVO	56.23	-8.3	-1661.6	23.03
2026-01-07	NVO	56.56	-8.3	-1547.5	23.03
2026-01-08	NVO	57.35	-8.3	-2338.5	23.03
2026-01-09	NVO	58.83	-8.3	-1932.7	23.03
2026-01-12	NVO	59.85	-8.3	-2170.1	23.03
2026-01-13	NVO	59.63	-8.3	-2122.6	23.03
2026-01-14	NVO	58.92	-8.3	-2556.0	23.03
2026-01-15	NVO	57.12	-8.3	-2882.1	23.03
2026-01-16	NVO	62.35	-8.3	-497.6	23.03
2026-01-20	NVO	60.67	-7.9	-2278.8	23.03
2026-01-21	NVO	59.33	-7.9	-2725.3	23.03
2026-01-22	NVO	62.22	-7.9	-1016.4	23.03
2026-01-23	NVO	62.24	-7.9	-2170.9	23.03
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	NVO	0	-1.39	0.85
2025-12-29	NVO	0	-1.53	0.85
2025-12-30	NVO	0	-1.53	0.85
2025-12-31	NVO	0	-1.53	0.85
2026-01-02	NVO	0	-1.53	0.85
2026-01-05	NVO	0	-1.32	0.85
2026-01-06	NVO	0	-1.32	0.85
2026-01-07	NVO	0	-1.32	0.85
2026-01-08	NVO	0	-1.32	0.85
2026-01-09	NVO	0	-1.32	0.85
2026-01-12	NVO	0	-1.33	0.85
2026-01-13	NVO	0	-1.33	0.96
2026-01-14	NVO	0	-1.33	0.96
2026-01-15	NVO	0	-1.33	0.96
2026-01-16	NVO	0	-1.33	0.96
2026-01-20	NVO	0	-1.66	0.96
2026-01-21	NVO	0	-1.66	0.96
2026-01-22	NVO	0	-1.66	0.96
2026-01-23	NVO	0	-1.66	0.96
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

1.02

Avg. EPS Est. Current Quarter

5.82

Avg. EPS Est. Next Quarter

5.08

Insider Transactions

Institutional Transactions

-1.66

Beta

0.66

Average Sales Estimate Current Quarter

77280

Average Sales Estimate Next Quarter

70302

Fair Value

52.89

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-68.5

Target Price

61.57

P/E

18.14

Forward P/E

17.99

PEG

3.55

P/S

4.49

P/B

10.34

P/Free Cash Flow

20.97

EPS

3.43

Average EPS Est. Cur. Y

23.03

EPS Next Y. (Est.)

22.66

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

32.76

Relative Volume

1.39

Return on Equity vs Sector %

33.8

Return on Equity vs Industry %

24.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.07

EBIT Estimation

-2170.9

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 78554

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

Float Short %

5.71

Margin Of Safety %

Put/Call OI Ratio

0.32

EPS Next Q Diff

1.57

EPS Last/This Y

4.36

EPS This/Next Y

6.97

Price

235.31

Target Price

268.09

Analyst Recom

1.18

Performance Q

16.13

Relative Volume

1.97

Beta

0.43

Ticker: ASND

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	ASND	209.1	0.19	0.17	14457
2025-12-29	ASND	211.02	0.20	0.17	14528
2025-12-30	ASND	209.61	0.20	0.43	14688
2025-12-31	ASND	213.33	0.20	0.86	14754
2026-01-02	ASND	213.43	0.23	0.36	15963
2026-01-05	ASND	213.17	0.25	0.55	16710
2026-01-06	ASND	209.35	0.27	3.69	17330
2026-01-07	ASND	212.9	0.29	0.24	17576
2026-01-08	ASND	208.52	0.29	0.69	17953
2026-01-09	ASND	202.78	0.30	0.50	18027
2026-01-12	ASND	208.93	0.28	0.26	19702
2026-01-13	ASND	214.96	0.27	0.05	19848
2026-01-14	ASND	217.5	0.26	0.47	20173
2026-01-15	ASND	215.25	0.26	0.00	20269
2026-01-16	ASND	205.69	0.27	2.95	19639
2026-01-20	ASND	215.28	0.28	0.12	12088
2026-01-21	ASND	216.78	0.31	0.72	12695
2026-01-22	ASND	228.67	0.31	0.42	12727
2026-01-23	ASND	235.41	0.32	0.44	13126
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	ASND	208.89	77.7	375.5	-3.22
2025-12-29	ASND	211.10	77.7	381.8	-3.22
2025-12-30	ASND	209.48	77.7	378.3	-3.22
2025-12-31	ASND	213.29	77.7	384.0	-3.22
2026-01-02	ASND	213.29	77.7	380.2	-3.22
2026-01-05	ASND	213.24	77.7	380.3	-3.22
2026-01-06	ASND	209.30	77.7	377.4	-3.22
2026-01-07	ASND	212.44	77.7	384.7	-3.22
2026-01-08	ASND	208.65	77.7	377.1	-3.22
2026-01-09	ASND	202.82	77.7	375.7	-3.22
2026-01-12	ASND	208.86	79.0	387.7	-3.22
2026-01-13	ASND	215.04	79.0	388.0	-3.22
2026-01-14	ASND	217.44	72.2	383.9	-3.22
2026-01-15	ASND	215.27	72.2	379.4	-3.22
2026-01-16	ASND	205.76	70.0	372.5	-3.22
2026-01-20	ASND	215.45	63.9	391.1	-3.22
2026-01-21	ASND	216.76	58.1	382.2	-3.22
2026-01-22	ASND	228.64	58.1	392.6	-3.22
2026-01-23	ASND	235.31	56.7	387.1	-3.22
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	ASND	0.00	1.83	5.60
2025-12-29	ASND	0.00	1.84	5.60
2025-12-30	ASND	0.00	1.84	5.60
2025-12-31	ASND	0.00	1.84	5.60
2026-01-02	ASND	0.00	1.84	5.60
2026-01-05	ASND	0.00	1.78	5.60
2026-01-06	ASND	0.00	1.78	5.60
2026-01-07	ASND	0.00	1.78	5.60
2026-01-08	ASND	0.00	1.78	5.60
2026-01-09	ASND	0.00	1.78	5.60
2026-01-12	ASND	0.00	1.78	5.60
2026-01-13	ASND	0.00	1.78	5.71
2026-01-14	ASND	0.00	1.78	5.71
2026-01-15	ASND	0.00	1.78	5.71
2026-01-16	ASND	0.00	1.78	5.71
2026-01-20	ASND	0.00	1.60	5.71
2026-01-21	ASND	0.00	1.60	5.71
2026-01-22	ASND	0.00	1.60	5.71
2026-01-23	ASND	0.00	1.60	5.71
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.17

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

0.4

Insider Transactions

Institutional Transactions

1.6

Beta

0.43

Average Sales Estimate Current Quarter

245

Average Sales Estimate Next Quarter

276

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

0.4

Max Drawdown 5-Year %

-60.5

Target Price

268.09

P/E

Forward P/E

56.37

PEG

P/S

19.96

P/B

P/Free Cash Flow

EPS

-4.25

Average EPS Est. Cur. Y

-3.22

EPS Next Y. (Est.)

3.75

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-35.52

Relative Volume

1.97

Return on Equity vs Sector %

106.6

Return on Equity vs Industry %

122.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.17

EBIT Estimation

387.1

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1017

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y